Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Revenue (2016 - 2025)

Historic Revenue for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $27.8 million.

  • Anika Therapeutics' Revenue fell 589.33% to $27.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.8 million, marking a year-over-year increase of 3055.34%. This contributed to the annual value of $119.9 million for FY2024, which is 73.27% down from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' Revenue is $27.8 million, which was down 589.33% from $28.2 million recorded in Q2 2025.
  • Over the past 5 years, Anika Therapeutics' Revenue peaked at $44.3 million during Q2 2023, and registered a low of -$2.9 million during Q4 2023.
  • In the last 5 years, Anika Therapeutics' Revenue had a median value of $34.3 million in 2021 and averaged $30.8 million.
  • Its Revenue has fluctuated over the past 5 years, first tumbled by 10778.04% in 2022, then surged by 115560.54% in 2024.
  • Over the past 5 years, Anika Therapeutics' Revenue (Quarter) stood at $35.8 million in 2021, then tumbled by 107.78% to -$2.8 million in 2022, then dropped by 4.02% to -$2.9 million in 2023, then surged by 1155.61% to $30.6 million in 2024, then dropped by 9.1% to $27.8 million in 2025.
  • Its last three reported values are $27.8 million in Q3 2025, $28.2 million for Q2 2025, and $26.2 million during Q1 2025.